PTC THERAPEUTICS, INC. Q3 FY2026 earnings call

Safiance Launch Momentum:

• Reached one-year mark with over 2,000 active patients globally and record Q3 revenue of $182 million.
• U.S. demand remains strong with steady growth across therapy-naive, tried-and-failed, and switch segments.
• International expansion continues, led by a strong launch in Japan and new patient access via named programs in other regions.
• Management emphasizes being in 'early innings' of the launch, targeting a $2 billion+ peak sales opportunity.

Commercial Strategy & Priorities:

• Three key priorities: unlocking therapy-naive adults, expanding adoption among KuVan switchers, and building real-world evidence for severe PKU cases.
• Implemented ambassador program leveraging patient champions for peer-to-peer sharing.
• Enhanced digital presence and center-specific penetration strategies using claims data.

Pipeline Updates:

• Acquired ST920 (Fabry disease gene therapy) at BLA stage; expects rolling submission in Q4 2026 and potential approval/launch in 2027.
• Vodafone (Huntington’s Disease): Type C meeting rescheduled to Q1 2027 due to FDA scheduling; Phase 3 PIVOT-HD trial enrollment progressing well.
• Reticulon Frigidus Ataxia: Initiated PROVE-FA global trial.
• PTC844 (Rheumatoid Arthritis): Initiated Phase 2A study to confirm dose-response relationships.
• PTC612 (NLRP3 inhibitor): Phase 1 study progressing; focusing on rare pulmonary indications.
• PTC303 (Splicing modulator): On schedule to enter clinic in 2027 for DM1 and Huntington’s.

Financial Discipline:

• Maintaining effective expense management to achieve cash flow breakeven in 2026.
• Strong adherence rates (~90% renewal, low 20% cumulative discontinuations) reinforcing long-term value.

Total revenue for Q3 2026 reached $358 million, with product revenue of $276 million. The commercial portfolio generated $276 million in net product revenue, representing over 100% year-over-year growth. Key segment contributions include: Safiance (referred to as Sophia/Suffiance in transcript) at $182 million; the DMD franchise at $74 million total, broken down into Translarna ($49 million) and Amondys 45 (Amplaza/Implaza) ($25 million); and royalty revenue from E-Brisdy at $82 million. Safiance accounted for approximately 66% of total product revenue.

• Raised full-year 2026 product revenue guidance to $960–$990 million (previously lower).
• Raised full-year 2026 total revenue guidance to $1.29–$1.32 billion.
• Expects 64%–69% year-over-year growth in product revenue.
• Maintains goal of achieving cash flow breakeven in 2026 through disciplined expense management.
• No specific quarterly guidance provided, but Q4 expected to benefit from continued Safiance momentum despite seasonal headwinds.

• Regulatory delays: Vodafone Type C meeting shifted to Q1 2027 due to FDA scheduling constraints.
• Generic competition: Impact of generic entry on Amplaza pricing and Translarna revenue (no further large government orders expected post-Q3 Russia deal).
• Market access uncertainty: Pricing and reimbursement negotiations in Europe (Germany, France, Spain, Italy) remain ongoing, with finalization expected in H1 2027.
• Commercial execution risk: Despite strong start, vast majority of eligible PKU patients (approx. 85% in U.S.) have not yet started Safiance; switching dynamics require sustained effort.
• Pipeline execution: Dependence on successful trials for Vodafone, RetAtaxia, and ST920 approval timeline.

Q: Analyst asked about Safiance launch stage and growth trajectory in US vs ex-US. / A: CEO stated they are in early innings with only ~2,000 of 58,000 global patients treated. US is in steady, durable growth phase after initial acceleration; ex-US will see acceleration points as new markets gain access in 2027. Majority of peak revenue expected from US, though patient count may be higher internationally. Confident in $2B+ peak opportunity.

Q: Analyst asked if FDA's focus on tailored rare disease trials impacts their pipeline strategy. / A: CEO noted FDA alignment between fever and CDER is critical. Emphasized bespoke approaches for each therapy rather than standard diabetes/hypertension models. Mentioned upcoming discussions on Vodafone and Fabry program as examples of this flexible framework.

Q: Analyst asked about US vs ex-US revenue split magnitude and if US launch is slowing. / A: CEO clarified that while US revenue will be majority, patient numbers may be larger outside US due to population size. US is in steady growth, not slowing; international growth driven by Japan launch and future European access. Reiterated confidence in reaching peak targets.

Q: Analyst asked about drivers for raised guidance and impact of DMD franchise. / A: CEO attributed most guidance increase to Safiance enthusiasm. DMD franchise contributed less than earlier in 2026 due to generic pressure on Amplaza and lack of repeat large government orders for Translarna. Safiance remains the primary growth engine.

Q: Analyst asked about appetite for additional M&A given $2B cash balance. / A: CFO confirmed disciplined approach to BD. Stated they have global infrastructure capacity and cash flexibility to pursue value-creating transactions that support top-line growth and profitability, similar to the ST920 acquisition.